Category
24 plain-language articles on metabolic health — the physiology, the compounds, and what the evidence actually shows.
24 articles
Stress, cortisol, and stubborn belly fat
The pattern is unmistakable once you see it. Weight that concentrates in the midsection. A waistline that creeps up while the rest of the body changes less. A softness around the abdomen that doesn't respond to longer workouts or stricter eating. And underneath, almost always, a life that's been running on too much stress for too long. "Cortisol belly fat" sounds like wellness shorthand. It's actually a precise description of a well-mapped mechanism.
Why diet and exercise stopped working
You're doing everything you used to do. The same training, the same meal pattern, the same discipline that worked in your twenties or early thirties. And nothing is moving. The scale is stuck. The energy isn't returning. The mirror keeps reflecting back a body that doesn't match the effort you're putting in. The advice you keep getting — eat less, move more — is technically true, and it's not landing.
Insulin resistance: the metabolic shift no one talks about
You're eating the way you always have. Maybe better. The pants don't fit the way they used to. The midafternoon crash after lunch feels heavier. The scale won't move even on weeks you're hitting the caloric deficit honestly. Your annual labs come back "normal." And the gap between what the numbers say and what you feel keeps widening.
What people are reporting about AICAR — the "exercise in a pill"
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
AICAR — the AMPK agonist and the "exercise mimetic" conversation
In 2008, a paper came out of the Salk Institute that generated the kind of headlines science usually doesn't get to produce. Sedentary mice that had received a compound called AICAR for four weeks ran 44 percent longer on a treadmill than untreated mice, despite having done no prior training. The researcher behind it, Ronald Evans — a Howard Hughes Investigator who had spent years studying the genetics of exercise adaptation — described it as a potential exercise pill. The phrase landed. It bounced across science publications and general media, and it planted an idea that persists: that the metabolic benefits of exercise might be chemically replicable, that the adaptation could be achieved without the effort.
Cagrilintide and the amylin story — why CagriSema is generating interest
For about a decade, obesity pharmacology was a field that kept almost delivering. The compounds that made it through the regulatory process were real drugs with real effects, but the effect sizes were modest by the standard of what the clinical need demanded — five percent body weight, eight percent, numbers that mattered medically but didn't shift the felt experience of treatment from incremental to transformative. Then the GLP-1 receptor agonists arrived at full dose in obesity indications, and the conversation changed. Fifteen to twenty percent body weight reduction in clinical trials was a number that made physicians and patients alike recalibrate their model of what was pharmacologically achievable. The question that immediately followed — among researchers, clinicians, and the industry watching closely — was not whether this was sufficient, but what would come next.
What people are reporting about Cagrilintide and the CagriSema combination
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
The last fifteen pounds — what's different about plateau weight that won't move
You lost the first twenty-five pounds with something that resembled consistency, if not ease. You cleaned up the diet, you trained more seriously, you tracked what you ate for long enough to understand your actual patterns. The number on the scale moved. Not fast — never as fast as the protocols promised — but it moved, and the trajectory was real, and you felt legitimately different in your body as it happened. And then, somewhere in the last fifteen pounds, everything stopped. Not slowly. It just stopped. The eating is the same. The training is arguably better — more structured, more progressive, more targeted to the body composition outcome you want. The sleep has improved. The stress hasn't disappeared but you're managing it. And the number hasn't changed meaningfully in four months, maybe six. The body you're in now is not the body you're trying to live in. The gap between them is fifteen pounds, and no amount of additional discipline has closed it.
Food noise — the obsession with eating you can't think your way out of
It starts before breakfast is over. You're still eating and already thinking about lunch — what you'll have, whether that's too much, whether you should have eaten what you just ate, what you'll do to compensate. By mid-morning there's a quiet negotiation running in the background: if you skip the afternoon snack, you can have a real dinner. If you have the good lunch, maybe just a small dinner. You're not even hungry. You're just... in it. The loop is running whether you want it to or not.
GLP-1s and alcohol — the off-label effect nobody planned for
You started semaglutide for your weight, and somewhere around week six you noticed something nobody warned you about. The glass of wine you poured at the end of the workday sat on the counter. Not because you decided not to drink it. You just forgot it was there. The craving that usually showed up around 6 PM — specific, familiar, a little impatient — didn't. And then the next night, same thing. And the night after that. You mentioned it to a friend who was also on a GLP-1 and she laughed and said she'd stopped buying wine entirely because she kept letting bottles go bad.
Weight regain after stopping a GLP-1 — what's biological, what's behavioral, what to do
You lost thirty pounds over nine months. You ate less without fighting yourself about it, which was new. The background noise of food — the constant low-level negotiation between wanting something and deciding not to have it — went quiet in a way it never had before. And then, for whatever reason — cost, the medication becoming unavailable, your provider recommending a break, your own decision — you stopped. The quiet lasted maybe three weeks. And then the noise came back.
Glycation and AGEs — the sugar-driven aging mechanism
When a pathologist examines the aorta of someone who died of cardiovascular disease, one of the things they look at is the compliance of the vessel wall — how much it stretches under pressure. In a young, healthy aorta, the wall is elastic; it expands with the pulse and recoils between beats, absorbing and releasing energy like a spring. In an aged or diseased aorta, the wall is stiff. It doesn't give. The left ventricle has to work harder to push against it, and blood pressure rises. The structural difference between the two vessels, in large part, comes down to chemistry that began accumulating years or decades before the heart failure or the stroke or the aneurysm made the stiffness clinically apparent.
The HCG diet — why it never worked and what the research actually says
In 1954, a British physician named Albert T.W. Simeons published a paper in The Lancet titled "The Action of Chorionic Gonadotrophin in the Obese." He had been working in Rome, treating patients with obesity, and he had developed a theory. The theory was this: HCG, the hormone present in high concentrations during pregnancy, had a special property — it mobilized fat stored in "abnormal deposits," the kind of stubborn fat that collects around the hips, thighs, and abdomen in ways that conventional dieting failed to touch. Combine HCG injections with a 500-calorie-per-day diet, Simeons argued, and you would lose fat from those deposits specifically, while sparing muscle, without the hunger that would normally make a 500-calorie diet intolerable. The weight would come off in the right places. The hunger would be manageable. The results would be dramatic and lasting.
What people are reporting about Mazdutide, the dual GLP-1/glucagon peptide
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
Microdose GLP-1: who it's actually for, and what "microdose" really means
You lost the weight. Not all of it, but enough — and then life happened, or the stress came back, or perimenopause shifted the whole calculus, and slowly the scale started moving in the wrong direction again. Not dramatically. Five pounds, then eight. The cravings that had gotten quiet started getting louder. You've heard about GLP-1 medications, but the idea of full-dose — the nausea, the muscle loss concerns, the appetite suppression so aggressive you stop eating enough protein — feels like more than the problem warrants. There should be something in between, and you're not sure whether that's a real clinical option or just wishful thinking.
Microdose vs full-dose GLP-1 — picking the right intensity for the right goal
You've done the reading. You know GLP-1 receptor agonists exist. You know they work. But the conversation around them — the before-and-afters, the celebrity speculation, the prescribing provider ads — all seems to point at one thing: the full dose, the dramatic weight loss, the transformation narrative. And that's not quite what you're looking for. Or maybe it is, and you're not sure. You're trying to figure out whether the intensity of the intervention matches the intensity of your situation, and nobody has given you a framework for that.
What people are reporting about Setmelanotide for rare genetic obesity
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
Setmelanotide and genetic obesity — what targeted MC4R activation looks like
The child eats constantly. Not the way toddlers go through phases of wanting snacks — this is something different, something the parents describe to pediatricians with a kind of desperation, the word "insatiable" appearing and reappearing in every appointment. The weight gain started before age two. The hunger doesn't respond to meals the way hunger is supposed to. Doctors check for behavioral causes. Nutritionists are consulted. Families restructure their entire kitchens and still wake up to find a child crying for food in the middle of the night.
What people are reporting about Survodutide, the MASH-targeted dual agonist
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
Why you can't quit the thing you meant to quit — what biology contributes
You made the decision months ago. You were going to drink less — or stop. Cut the sugar. Stop vaping. Spend less time on the thing that was eating your evenings. You meant it. You started. You held it for a few days, maybe a week, and then something happened — a stressful afternoon, a social situation, a moment of restlessness that required an answer — and you were back in the pattern you'd decided to leave. You tried again. You've tried several times by now. Each attempt begins with genuine intent and ends in a version of the same place. The explanation offered by most of your life — by culture, by most advice — is that you lack willpower. That the difference between people who quit and people who don't is discipline, character, sustained commitment to the thing they said they wanted.
The hangover at one drink — what diminished alcohol tolerance is signaling
One glass of wine with dinner. Not two, not a bottle — one. And you wake at 3am with a dull headache behind the eyes, your face still faintly warm, your sleep shallow and broken, and a low mood the next morning that doesn't lift until afternoon. The flush came on within minutes of finishing the glass — the cheeks, the warmth, maybe the heart beating a little faster than it should. The next day you feel vaguely poisoned, out of proportion to anything you actually drank. You remember when a glass of wine was just a glass of wine. Now it costs you a day.
The mood after alcohol that's different from how it used to be
You used to drink two glasses of wine at a dinner party and feel pleasantly social for a few hours and wake up fine. That is no longer what happens. What happens now is the dinner party is fine, maybe genuinely enjoyable in the moment, and then the next day there's a shadow over everything — a low-grade anxiety that's out of proportion to anything you can point to, a flatness that takes the first half of the day to lift, sometimes the second half too. Occasionally it doesn't fully lift by day two. The night itself: broken sleep, a heart that seems to be working harder than it should be at three a.m., something you might describe as a low-level internal buzzing that wasn't there in your 30s. The red wine that you loved for years now sometimes produces a flush and a headache that arrives before you'd expect it. You've tried switching to white wine, to better wine, to less. The advice you consistently receive is: drink less. Which is accurate. And which doesn't explain why the same amount now produces a different consequence than it did before.
The shortness of breath on stairs — what new effort intolerance is signaling
It's one flight of stairs — the same flight you've climbed a hundred times to the office, the apartment, the platform — and somewhere around the top you notice you're breathing harder than the climb should cost. You reach the landing and you pause, just for a beat, before you say the thing you were about to say, because the words and the breath are competing for the same air. Maybe you cover it by checking your phone. Maybe nobody notices. But you noticed, and what stays with you isn't the breathlessness itself so much as the small flush of embarrassment, and the quiet recognition that this didn't used to happen. The stairs are the same. You are the one that changed.
Vesugen — the vascular endothelium bioregulator
Arterial stiffness doesn't announce itself the way a heart attack does. It accumulates across years — a gradual loss of compliance in vessel walls that used to spring back, a creeping rise in systolic blood pressure that your doctor notes but doesn't yet treat, a resting heart rate that has ticked up slightly without obvious cause. Your arteries at 50 behave differently than they did at 30, and not in ways that show up on a single test. They show up in the aggregate of things that are harder to measure: exercise tolerance that has plateaked, recovery from exertion that takes longer, blood pressure that runs higher on difficult weeks than it used to. None of this is a diagnosis. All of it is real.